ABSTRACT
Various cardiovascular complications have been reported in patients with coronavirus disease 2019. Common complications include acute myocardial injury, myocarditis, arrhythmia, pericarditis, heart failure, and shock. We present a case of cor pulmonale diagnosed with serial point of care ultrasound. Given the current shortage of personal protective equipment (PPE) and high infectivity of this virus, we acknowledge the utility of this tool in obtaining important clinical information while minimizing exposure and PPE consumption.
Subject(s)
Betacoronavirus , Coronavirus Infections/complications , Echocardiography , Heart Failure/diagnostic imaging , Pneumonia, Viral/complications , Point-of-Care Systems , Pulmonary Heart Disease/diagnostic imaging , Aged , COVID-19 , Electrocardiography , Fatal Outcome , Heart Failure/diagnosis , Heart Failure/etiology , Humans , Male , Pandemics , Pulmonary Heart Disease/etiology , Respiratory Distress Syndrome/etiology , SARS-CoV-2 , Ventricular Dysfunction, RightABSTRACT
OBJECTIVES: ST-segment elevation myocardial infarction (STEMI) can be associated with many conduction disturbances including complete atrioventricular block (CAVB). CAVB complicating STEMI resulted in an increased mortality before the modern era of primary percutaneous coronary intervention (PCI). The aim of this study was to ascertain the rate and risk factors for CAVB in STEMI patients undergoing rapid reperfusion with PCI. METHODS: We analyzed 223 patients presenting with STEMI. Patient characteristics, procedural characteristics, and in-hospital data were compared between patients with and without CAVB. RESULTS: Out of 223 patients, 174 underwent PCI; the majority (87%) was African-American. CAVB was present in 8 patients (4.6%), and 6 of them had RCA occlusion. Independent predictors of CAVB included diabetes mellitus, female gender, lower systolic and diastolic blood pressure, and inferior-lateral/lateral STEMI. Ten patients (5.7%) required temporary pacing at presentation; only 1 patient required permanent pacing before discharge. No patient with anterior STEMI developed CAVB. CONCLUSIONS: The incidence and in-hospital mortality rate of CAVB in patients with STEMI who underwent primary PCI was reduced when compared to data from the thrombolytic era. This may be due to faster flow recovery in the infarct-related artery achieved with PCI.
Subject(s)
Atrioventricular Block/complications , Hospital Mortality , Percutaneous Coronary Intervention/adverse effects , ST Elevation Myocardial Infarction/therapy , Adult , Aged , Atrioventricular Block/diagnosis , Atrioventricular Block/mortality , Electrocardiography , Female , Humans , Incidence , Kaplan-Meier Estimate , Logistic Models , Male , Middle Aged , Multivariate Analysis , New York , Percutaneous Coronary Intervention/mortality , Retrospective Studies , Risk Factors , ST Elevation Myocardial Infarction/mortality , Treatment OutcomeABSTRACT
Myocardial infarction with non-obstructive coronary arteries (MINOCA) is defined by the presence of positive cardiac biomarkers with clinical evidence of infarction, the absence of significant coronary stenosis (≥50%) on angiography, and the lack of alternative diagnosis for the index presentation. MINOCA poses a diagnostic and therapeutic challenge due to the various pathophysiologic mechanisms underlying its presentation. Coronary artery plaque disruption is recognized as a crucial mechanism contributing to MINOCA. Plaque rupture and thrombus formation with subsequent myocardial ischemia may occur without significant luminal narrowing. A high index of suspicion is needed to make an early diagnosis. Here, a 68-year-old African American male patient presented with substernal chest pain, nonspecific ST segment changes on electrocardiogram, and elevation in cardiac biomarkers only one day after undergoing diagnostic cardiac catheterization that revealed non-obstructed coronary arteries. This case provides an example of MINOCA occurring secondary to suspected coronary artery plaque disruption in the setting of recent cardiac catheterization.
ABSTRACT
Several reports have described the successful insertion of implantable cardioverter defibrillator (ICD) in patients with a persistent left superior vena cava (PLSVC). The implanters have used various techniques to achieve appropriate lead placement. In our case, the use of a long sheath, guided by a deflectable catheter, not only facilitated proper implantation of the lead, but also provided a unique position of the dual-coil lead. This resulted in a very low defibrillation threshold (DFT). We describe a case of a patient found to have a PLSVC at implant who after successful insertion of the ICD exhibited DFT ≤ 5 J.
Subject(s)
Defibrillators, Implantable , Electrodes, Implanted , Prosthesis Implantation/methods , Vena Cava, Superior/abnormalities , Vena Cava, Superior/surgery , Differential Threshold , Humans , Male , Middle AgedABSTRACT
Sinus bradycardia and associated isorhythmic AV dissociation may be seen during dobutamine stress echocardiography. This phenomenon is usually considered a benign peri-procedural event and is thought to be secondary to the Bezold-Jarisch reflex, with profound heart rate decrease secondary to a marked increased in vagal efferent discharge. To the best of our knowledge, dobutamine stress echocardiography unmasking clinically relevant sinus node dysfunction has never been reported. We report a case of a 50-year-old man presenting with chest pain and a history of syncope, who had worsening sinus bradycardia with isorhythmic AV dissociation during dobutamine stress echocardiography. An invasive electrophysiological study revealed marked sinus node dysfunction. The patient was referred for the insertion of a permanent pacemaker for sinus node dysfunction, chronotropic incompetence and symptomatic bradycardia. Dobutamine-associated bradycardia may not always be a benign peri-procedural physiologic effect, as in this case it may unmask clinically significant sinus node dysfunction.
Subject(s)
Echocardiography, Stress , Sick Sinus Syndrome/diagnosis , Diagnosis, Differential , Humans , Male , Middle Aged , Pacemaker, Artificial , Sick Sinus Syndrome/diagnostic imaging , Sick Sinus Syndrome/therapyABSTRACT
OBJECTIVES: QT dispersion (QT(d)) measures the variability of the ventricular recovery time. QT(d) may identify patients at risk for ventricular arrhythmias and sudden cardiac death (SCD). The purpose of our study was to determine the effect of obstructive sleep apnea (OSA) on QT(d). METHODS: There were 199 patients studied: 101 patients (28 women, 73 men) with OSA diagnosed in our sleep center and 98 patients (49 women, 49 men) without OSA from the outpatient clinic, representing the control group. QT intervals (milliseconds) were measured in each of the 12 leads of a standard surface electrocardiogram during wakefulness and QT(d) calculated (QT(max) - QT(min)). QT(c)(d), which corrects for heart rate, was also calculated. RESULTS: Mean age and heart rate were similar in men and women with or without OSA. Control patients exhibited a significant difference (p < 0.001) in QT(d) between men (48 ± 19) and women (31 ± 13). Men and women with OSA had similar QT(d) (56 ± 35 vs. 54 ± 21) but higher QT(d) compared to the control group. QT(c)(d) results were similar to QT(d). CONCLUSIONS: Patients with OSA and no structural heart disease have a higher QT(d)/QT(c)(d) compared to an overtly healthy patient population, possibly serving as a marker for an increased risk of SCD.
Subject(s)
Death, Sudden, Cardiac/etiology , Heart Conduction System/physiopathology , Sleep Apnea, Obstructive/physiopathology , Adult , Case-Control Studies , Electrocardiography , Female , Humans , Male , Middle Aged , Sleep Apnea, Obstructive/complicationsABSTRACT
Subacute cardiac tamponade (SCT) is a potentially life-threatening condition that requires immediate medical attention. Combining careful history taking, focused physical exam, and the use of point of care ultrasound (POCUS) for early diagnosis with aggressive management can minimize potential complications. In patients with severe hypothyroidism and myxedema coma, clinical signs of cardiac tamponade may be masked and lead to delayed diagnosis. We present a case of a 67-year-old female with SCT secondary to myxedema coma, necessitating emergent pericardiocentesis following the identification of a large pericardial effusion with tamponade physiology. This case highlights the importance of thorough history taking with focused diagnostic workup, including POCUS in patients with an insidious presentation of SCT.
ABSTRACT
BACKGROUND: During the COVID-19 pandemic, the need for judicious use of diagnostic tests and to limit personnel exposure has led to increased use and dependence on point-of-care ultrasound (POCUS) examinations. We reviewed POCUS findings in patients admitted to the intensive care unit (ICU) for acute respiratory failure with COVID-19 and correlated the findings to severity of illness and 30-day outcomes. METHODS: Patients admitted to the ICU in March and April 2020 were reviewed for inclusion (acute hypoxemic respiratory failure secondary to COVID-19 pneumonia; documentation of POCUS findings). RESULTS: Forty-three patients met inclusion criteria. B lines and pleural thickening were associated with a lower PaO2/FiO2 by 71 (P = .005; adjusted R 2 = 0.24). Right ventricle (RV) dilation was more common in patients with 30-day mortality (P = .02) and was a predictor of mortality when adjusted for hypertension, diabetes mellitus, and age (odds ratio, 12.0; P = .048). All patients with RV dilation had bilateral B lines with pleural irregularities. CONCLUSIONS: Although lung ultrasound abnormalities are prevalent in patients with severe disease, RV involvement seems to be predictive of outcomes. Further studies are needed to discern the etiology and pathophysiology of RV dilation in COVID-19.
ABSTRACT
BACKGROUND: Platelet glycoprotein IIb/IIIa inhibitors are administered during percutaneous coronary intervention as a bolus followed by infusion. The need for an infusion was established by the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial conducted during the percutaneous transluminal coronary balloon angioplasty (PTCA) era, when the threat of acute thrombotic complications prevailed over concerns regarding bleeding, and stenting was considered an adverse event. METHODS: The EPIC trial randomized high-risk PTCA patients to 3 arms: placebo, abciximab bolus only, and abciximab bolus plus infusion. The present analysis of the EPIC outcomes was done at 6-hour intervals during the first 24 hours after PTCA to identify any early benefit derived from the abciximab bolus-only arm. RESULTS: At 6 hours after randomization, the primary composite end point of death, myocardial infarction, or urgent intervention was significantly reduced by 46% with abciximab bolus-only compared with placebo (2.9% vs 5.3%; P = .022), which is mainly due to a reduced rate of urgent intervention. There was also a numerical but not statistically significant reduction in myocardial infarction rate using abciximab bolus-only compared with placebo. A lower bleeding rate in the bolus-only arm compared with bolus plus infusion has been reported. CONCLUSIONS: As stenting and thienopyridine use have become routine, there has been a decrease in the incidence of acute closure and an increasing concern for bleeding complications after percutaneous coronary intervention, which potentially may be addressed by adopting a bolus-only glycoprotein IIb/IIIa inhibitor strategy. The early protective ischemic effect of abciximab bolus-only observed in the EPIC trial may be relevant in this regard.
Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Antibodies, Monoclonal/administration & dosage , Coronary Thrombosis/prevention & control , Immunoglobulin Fab Fragments/administration & dosage , Myocardial Ischemia/prevention & control , Platelet Aggregation Inhibitors/administration & dosage , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Abciximab , Antibodies, Monoclonal/adverse effects , Coronary Artery Disease/therapy , Coronary Thrombosis/etiology , Humans , Immunoglobulin Fab Fragments/adverse effects , Myocardial Ischemia/etiology , Platelet Aggregation Inhibitors/adverse effects , Postoperative Hemorrhage/chemically induced , Time FactorsABSTRACT
OBJECTIVES: The goal of this study was to analyze the incidence and predictors of postprocedure chest pain (PPCP) after percutaneous coronary intervention (PCI) and its correlation with clinical restenosis. BACKGROUND: Chest pain after PCI occurs frequently even in the absence of procedural events and is considered to be due to vasospasm or coronary artery stretch. The short- and long-term significance of PPCP after otherwise successful stenting is not clear. METHODS: We analyzed 1,362 patients undergoing coronary stenting for PPCP, procedural and in-hospital events, 30-day major adverse cardiac events, and target vessel revascularization (TVR) at 6 to 9 months. RESULTS: There were 488 patients with PPCP and, of these, 312 patients were excluded due to procedural events. The remaining 176 patients with PPCP were compared with 874 patients without PPCP. Creatine kinase-MB isoenzyme elevation occurred in 25.6% of the PPCP group versus 9.6% of the no PPCP group (p < 0.001). Despite similar reference vessel diameter, the PPCP group had larger postprocedure minimum lumen diameter, higher stent-to-vessel ratio, and higher inflation pressure versus the no PPCP group (p < 0.01). At 30 days, the emergency room visits and repeat catheterization (16% vs. 2.7%; p < 0.001) were higher in the PPCP group versus the no PPCP group, but repeat intervention was similar. At 6- to 9-month follow-up, the TVR was significantly higher in the PPCP group compared with the no PPCP group (29.5% vs. 16.6%; p < 0.01). CONCLUSIONS: Our analysis suggests micromyonecrosis and vessel stretch as causes of PPCP. Postprocedure chest pain is associated with similar short-term outcome as no PPCP, but has higher restenosis, perhaps mediated by deep vessel wall injury. Therefore, PPCP may identify patients at high risk for restenosis.
Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Atherectomy, Coronary/adverse effects , Chest Pain/etiology , Coronary Restenosis/epidemiology , Postoperative Complications/etiology , Stents/adverse effects , Aged , Chest Pain/epidemiology , Coronary Restenosis/etiology , Creatine Kinase/blood , Creatine Kinase, MB Form , Female , Humans , Incidence , Isoenzymes/blood , Male , Middle Aged , Myocardial Ischemia/etiology , Myocardial Revascularization , Postoperative Complications/epidemiology , Predictive Value of Tests , Risk , Time FactorsABSTRACT
BACKGROUND: The seven-component Thrombolysis In Myocardial Infarction (TIMI) score has been used to risk stratify, and to guide the medical management of, patients with unstable angina or non-ST-elevation myocardial infarction. We assessed the usefulness of the risk score in predicting in-hospital and 30-day outcomes in such patients who were undergoing percutaneous coronary intervention. METHODS: Using the TIMI score, 2501 patients with unstable angina or non-ST-elevation myocardial infarction were divided into low-risk (zero to two risk factors; n = 974), intermediate-risk (three to four risk factors; n = 1339), and high-risk (five to seven risk factors; n = 188) groups, and outcomes were compared. RESULTS: Angiographic/clinical success and the rate of minor procedural events were similar among the three groups. A higher TIMI risk score was associated with more cardiac comorbid conditions and more complicated angiographic lesions: longer lesions (P = 0.0009), more thrombotic lesions (P = 0.03), more multivessel disease (P <0.0001), and more American College of Cardiology/American Heart Association type B2/C lesions (P = 0.05). Although the risk score did not predict interventional technical success or intraprocedural complications, a high score was associated with prolonged hospital stay, higher postprocedural peak troponin levels, and 30-day major adverse cardiac events. Stepwise logistic regression showed that in conjunction with lesion length and patient sex, a high score was an independent predictor of 30-day major adverse cardiac events (odds ratio = 2.3; 95% confidence interval: 1.1 to 4.1; C statistic = 0.62). CONCLUSION: Although a higher TIMI risk score in patients with unstable angina or non-ST-elevation myocardial infarction who were undergoing percutaneous coronary intervention correlated with adverse clinical outcome, the score alone cannot be used to guide diagnostic or therapeutic strategies.
Subject(s)
Angioplasty, Balloon, Coronary , Coronary Disease/therapy , Acute Disease , Aged , Aged, 80 and over , Biomarkers/blood , Coronary Angiography , Coronary Disease/blood , Coronary Disease/epidemiology , Coronary Vessels/metabolism , Coronary Vessels/pathology , Creatine Kinase/blood , Creatine Kinase, MB Form , Female , Follow-Up Studies , Humans , Incidence , Isoenzymes/blood , Length of Stay , Logistic Models , Male , Middle Aged , New York/epidemiology , Platelet Glycoprotein GPIIb-IIIa Complex/therapeutic use , Predictive Value of Tests , Risk Factors , Severity of Illness Index , Sex Factors , Statistics as Topic , Stroke Volume/physiology , Syndrome , Treatment Outcome , Troponin I/bloodABSTRACT
A 65 year-old woman developed tachycardia and hypotension during haemodialysis. The non-contact mapping system was used to localise the origin of focal atrial tachycardia, and showed a remote from the endocardium focus. We discuss techniques that are helpful in identifying the origin, the area of preferential conduction, and the endocardial breakthrough of tachycardia.
Subject(s)
Electrophysiologic Techniques, Cardiac/methods , Endocardium , Hypotension/etiology , Tachycardia/etiology , Aged , Catheter Ablation/methods , Dialysis/adverse effects , Female , Humans , Hypotension/physiopathology , Image Processing, Computer-Assisted/methods , Kidney Failure, Chronic/therapy , Tachycardia/physiopathologyABSTRACT
We present a patient at risk of sudden cardiac death in whom ventricular fibrillation was effectively treated by wearable automatic defibrillator. We discuss the technical aspects of the device, current indications for this therapy and outcomes.
Subject(s)
Defibrillators, Implantable , Ventricular Fibrillation/therapy , Death, Sudden, Cardiac/prevention & control , Humans , Male , Middle Aged , Risk Factors , Treatment OutcomeSubject(s)
Contrast Media/adverse effects , Diabetic Nephropathies/complications , Dopamine Agonists/therapeutic use , Fenoldopam/therapeutic use , Kidney Diseases/chemically induced , Kidney Failure, Chronic/complications , Triiodobenzoic Acids/adverse effects , Aged , Atherectomy, Coronary , Cardiac Catheterization , Female , Humans , Incidence , Kidney Diseases/prevention & control , Male , Risk Factors , StentsABSTRACT
Radiographic contrast nephropathy (RCN), acute worsening of renal function due to contrast agents, can occur in 15%-40% of patients with baseline renal dysfunction undergoing percutaneous coronary intervention (PCI) and is associated with increased morbidity and in-hospital mortality. The purpose of this study was to evaluate whether the selective dopamine-1 (DA-1) receptor agonist fenoldopam would be beneficial in patients with chronic renal insufficiency (CRI) undergoing PCI and also to design a protocol for prevention of RCN. We analyzed 150 consecutive patients with CRI [baseline serum creatinine (BSCr) +/- 1.5% mg] who underwent PCI and received fenoldopam during and after the procedure, in addition to saline hydration. RCN, defined as > 25% increase of BSCr 48-72 hr after PCI, occurred in 4.7% (n = 7) of 150 PCI patients receiving fenoldopam and 3.5% in diabetics (n = 85) vs. 6.1% in nondiabetics (n = 65; P = NS). No patients required dialysis. The observed 4.7% incidence of RCN with fenoldopam was significantly lower than 18.8% incidence in the historical control group (P < 0.001). Our data suggest that fenoldopam is a useful adjunct in the prevention of RCN during PCI, especially in diabetics.